Fagartikkel

• Andreas Austgulen Westin; Jørgen Gustav Bramness; Fatemeh Chalabianloo et al. (2013). Pregabalin bør flyttes til reseptgruppe B 615. (ekstern lenke)

Fremhevet artikkel i media

• Kjell Arne Johansson; Lars T. Fadnes; Karl Trygve Druckrey-Fiskaaen et al. (2026). forebygging.no - Det er å ta forebygging på alvor å hjelpe de som trenger det mest.. (ekstern lenke)

Konferanseposter

• Fatemeh Chalabianloo; Bettina Riedel; Jan Schjøtt et al. (2010). Hypersensitivity Reactions to Drugs: A Retrospective Analysis of Clinical Characteristics of Patients Consulting for Suspected Drug Hypersensitivity in an Allergy Center in Norway. (ekstern lenke)

Leserbrev

• Andreas Westin; Jørgen Gustav Bramness; Fatemeh Chalabianloo et al. (2013). Westin og medarbeidere svarer (om pregabalinmisbruk).. (ekstern lenke)

Studieprotokoll

• Fatemeh Chalabianloo; Lars T. Fadnes; Jon Mordal et al. (2025). Impact of dextroamphetamine substitution on the use of illicit amphetamines in adults with amphetamine dependence: a study protocol for the multicentre double blind randomised controlled trial ATLAS4Dependence. (ekstern lenke)
• Fatemeh Chalabianloo; Lars T. Fadnes; Jörg Assmus et al. (2025). Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR. (ekstern lenke)

Vitenskapelig artikkel

• Clara Lucas Guerra; Jørn Henrik Vold; Christer Frode Aas et al. (2025). Associations between happiness with social factors and opioid agonist therapy among people who inject drugs. (ekstern lenke)
• Camilla Djønne Moldekleiv; Astri J. Lundervold; Berit Skretting Solberg et al. (2025). Prevalence of substance use disorder in individuals with attention deficit/hyperactivity disorder: associations with sex and psychiatric comorbidity. (ekstern lenke)
• Elaheh Javadi Arjmand; Lise Margrete Thomassen; Karl Trygve Druckrey-Fiskaaen et al. (2025). The effect of fruit smoothie supplementation on psychological distress and biomarkers among people with opioid dependence receiving opioid agonist therapy: a randomized controlled trial. (ekstern lenke)
• Jørn Henrik Vold; Elinor Margrethe Chelsom Vogt; Anne Taraldsen Heldal et al. (2025). Low Testosterone Among Males in Opioid Agonist Therapy and Its Association With Fatigue and Psychological Distress. (ekstern lenke)
• Karl Trygve Druckrey-Fiskaaen; Tesfaye Madebo; Jan Tore Daltveit et al. (2025). Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy: A Randomized Clinical Trial. (ekstern lenke)
• Christer Frode Aas; Jørn Henrik Vold; Fatemeh Chalabianloo et al. (2024). Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders. (ekstern lenke)
• Prayash Chaudhary; Lars T. Fadnes; Steinar Fosse et al. (2024). Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation. (ekstern lenke)
• Jørn Henrik Vold; Anne Halmøy; Fatemeh Chalabianloo et al. (2023). Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study. (ekstern lenke)
• Jørn Henrik Vold; Fatemeh Chalabianloo; Else-Marie Løberg et al. (2023). The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: a randomized controlled trial. (ekstern lenke)
• Venkata Lakshmi Narasimha; Jenna Butner; Enjeline Hanafi et al. (2022). Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. (ekstern lenke)
• Fatemeh Chalabianloo; Gudrun Høiseth; Jørn Henrik Vold et al. (2022). Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. (ekstern lenke)
• Fatemeh Chalabianloo; Christian Ohldieck; Øystein Ariansen Haaland et al. (2021). Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence. (ekstern lenke)
• Fatemeh Chalabianloo; Lars T. Fadnes; Gudrun Høiseth et al. (2021). Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. (ekstern lenke)
• Lars T. Fadnes; Christer Frode Aas; Jørn Henrik Vold et al. (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). (ekstern lenke)
• Jørn Henrik Vold; Fatemeh Chalabianloo; Christer Frode Aas et al. (2021). Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. (ekstern lenke)
• Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit et al. (2020). Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. (ekstern lenke)
• Jørn Henrik Vold; Svetlana Skurtveit; Christer Frode Aas et al. (2020). Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; A prospective cohort study in Norway from 2013 to 2017. (ekstern lenke)
• Gabrielle Welle-Strand; Svetlana Skurtveit; Eli Kristine Fiksdal Abel et al. (2020). Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy. (ekstern lenke)
• Jørn Henrik Vold; Christer Frode Aas; Svetlana Skurtveit et al. (2020). Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. (ekstern lenke)
• Jørn Henrik Vold; Rolf Gjestad; Christer Frode Aas et al. (2020). Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. (ekstern lenke)
• Jørn Henrik Vold; Christer Frode Aas; Svetlana Skurtveit et al. (2020). Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; A national prospective cohort study in Norway from 2015 to 2017. (ekstern lenke)
• Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit et al. (2020). On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: A prospective cohort study from 2013 to 2017. (ekstern lenke)
• Fatemeh Chalabianloo; Andreas Westin; Eirik Skogvoll et al. (2019). Methadone serum concentrations and influencing factors: A naturalistic observational study. (ekstern lenke)
• Lars T. Fadnes; Christer Frode Aas; Jørn Henrik Vold et al. (2019). Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). (ekstern lenke)
• Marianne K. Kringen; Fatemeh Chalabianloo; Jean-Paul Anthony Bernard et al. (2017). Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. (ekstern lenke)
• Fatemeh Chalabianloo; Aud K Herland Berstad; Jan Schjøtt et al. (2011). Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Seenae Eum; Nicholas P. Vernacchia; Nia Doughty et al. (2024). Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis. (ekstern lenke)
• Fatemeh Chalabianloo; Lars T. Fadnes; Kjell Arne Johansson et al. (2024). Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. (ekstern lenke)
• Jørn Henrik Vold; Christer Frode Aas; Rafael Alexander Mo Leiva et al. (2019). Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.